Shots:
AI is revolutionizing healthcare, reshaping drug discovery, protein design, and precision therapeutics. Companies are now tackling previously “undruggable” targets and moving treatments through development pipelines faster than ever
The AI in the healthcare market is exploding. From a valuation of $26.57B in 2024, it is projected to reach $505.59B by 2033, growing at a CAGR of 38.8%. This rapid…
Shots:
Nabla Bio has entered into a multi-year research collaboration with Takeda to advance AI-driven design of protein therapeutics, leveraging Nabla Bio’s Joint Atomic Model (JAM)
Nabla Bio will deploy its proprietary JAM platform across Takeda’s early-stage programs to enable de novo antibody design for multiple targets, multi-specifics, challenging targets, & custom therapeutics
As per the…

